HK Stock Market Move | LAEKNA-B(02105) surged over 6% again LAE102 Phase I SAD study in the United States achieved positive results

LAEKNA-B (02105) rose by more than 6%, up 5.91% to HK$14.33 at the time of writing, with a trading volume of HK$17.6142 million. In terms of news, Lekai Pharmaceutical announced a collaboration with Eli Lilly and Company, successfully completing the Phase I single dose escalation study of LAE102 (a selectively targeted ActRIIA monoclonal antibody) in the United States. The results showed an encouraging, dose-dependent trend of muscle gain and fat loss after a single injection of LAE102. The company is currently actively planning a Phase II clinical trial to evaluate the combination therapy of LAE102 with incretin-based drugs for patients with high BMI and related complications. The company is in active discussions with potential partners to expedite the global development and commercialization process of LAE102, bringing this precision treatment to overweight and obese patients in need of innovative treatment options for achieving high-quality weight control.